Mamoon, thank you so much for joining us here today. Can you just take a moment to introduce yourself to our audience? Yeah, So Mimi Nayeb, I'm Senior VP and Head of Global Sales and Key Account Management at Gordon Farmer, and I'm based in Basel, Switzer. Corner Farmer has been known to work in the peptide space. Can you talk a little bit about your personal work in that area? Yeah, so I mean we have our site in Colorado and other sites in Europe. We have a couple of decades in experience in peptide manufacturing, development and manufacturing and we are expanding substantially. I mean as you know. There is this. High demand in GLP one agonist on the market and this is actually what is driving the peptide market today, the peptide market growth. And Cordon Pharma follows the growth obviously and as you can remember also during the COVID pandemic. And it was a lipid. So yesterday was the lipid, today it's peptide. So Corden Pharma follows, you know, the growth and where the patients need us most. Yeah, so and as you know, maybe just elaborate a little bit on the peptides, the GLP one especially because this is where we are becoming extremely known in the market. We have been expanding really substantially and as you know, these GLP one are long peptide sequences, sequences and very complex. You know, peptides molecules require a lot of processing engineering and in this case process engineering is even more important than process chemistry itself. It's a combination of both expertises that. Makes somehow Corden Pharma unique on this market. We have all of the streamlined supply chain with regard to solvent supply, waste treatment, raw material supply for such large peptide manufacturing. We're talking about metric tons. So we have done it all. But I would like also to stress the point that Cordon Pharma has not expanded only its large scale capacity in the peptide manufacturing, but also we have invested substantially in the small and medium scale both at Colorado and Frankfurt. So it's very important that we don't have the image of just the large scale peptide manufacturer. So we do really everything from in GMP from grams to metric tons, literally metric tons. So how do you manage to account for a peptide capacity? Yeah. So I think look, it is important to mention that the peptides manufacturing requires very specific. Capacity, very specific equipment, this is not competing with our other platforms. I think that's a very important message I would like to give to our customers. So both upstream processing as well as downstream processing with purification isolation, but tight capacity is completely different from the other type of capacities we use for small molecules, highly potent lipids, carbohydrates, etc. So this is really important to to highlight, yes, so there is no competition. Between the capacity in peptides and the other platforms, so we can completely grow both and Corden Pharma has more than ever the bandwidth to grow all of its six technology platforms. Let's talk about some of the other applications working with because we talked about in the peptides of everything, but I'm curious what other things you're working with. Yeah, so obviously it's a clear message from our CEO and our shareholders that we have and we continue to be committed to grow other platforms. You know we are. The company with with six pillars, actually 6 technology platforms. I can mention those again. We talked about the peptide, small molecules, injectables, oligonucleotide lipids and highly potent. So it's very, very important for all of us that Corn Pharma to continue growing those platforms. And through our commitment, we are actually expanding our capacity also in those other platforms. I can mention a few examples expansion, not only. In terms of capacity, but also investing in new technologies and I can mention a few of those, super fluid chromatography is one of them, flow chemistry to support our small molecule platform. Hot melt extrusion at our solid dose manufacturing plant in Plankstadt and then lipid nanoparticle formulation, you know the delivery of large molecules such as M RNA or plasmid DNA is very, very important area to be in. And Cordon Pharma has just completed an investment and as we speak our plant is being qualified in Italy at our injectable site in Italy to manufacture vaccines, M RNA based vaccines. So this is really showing. Somehow our commitment also to continue the growth in other platforms. Give me one big trend that you're seeing in the broader biopharma space. Yeah, that's an interesting question. Maybe you are where we have the TIDES conference coming up next week and this is really a very good opportunity to talk about the, you know, the large molecules such as in RNA as I mentioned the DNA or any type of gene therapy or gene editing based therapy. And you know the advances in drug delivery of large molecules has opened the door to those molecules to be investigated in not only infectious diseases as we have seen during the pandemic, but also for rare diseases, genetic diseases, but also immuno oncology, right. And just about like few weeks ago, we have seen another CAR T cell therapy approved by the FDA. I believe this is like the number six CAR T cell therapy. Globally and this one last one I believe was for CLL, so chronic lymphocytic leukemia. There's another cancer, blood cancer therapy. I think you know we will see a lot of I would say a mix of large molecules or biomolecules addressing the same indication than what we have seen as of today with small molecules, peptides, oligonucleotides and other type of molecules. Thank you so much for joining us. We really appreciate you taking the time to join us. Thank you.
Want to learn more about the application of flow chemistry and PAT in crystallization process development within a CDMO environment? Join our scientific experts presenting posters at the BOSS XVIII symposium in Liège, Belgium, where we are proud to be Gold sponsor!
Today, come and discuss with Dr. Clemens Horn about the benefits of Flow Chemistry. Tomorrow and Thursday, discuss with Dr. Tobias Wedel about the benefits of developing robust crystallization processes with the help of PAT.
#BOSS_Symposium#BOSSXVIII#flowchemistry#crystallisation#cdmo
Summer Events Initiative: Giving Back to Our Community
At CordenPharma we believe in the importance of giving back to the community and in the power of making a positive impact, not just in our industry but in the society as a whole. Our summer events are the perfect occasion to do this!
We're very proud to support twelve healthcare organizations with donations towards diverse diseases, in many of our business focus areas. These contributions are a way for us to participate meaningfully, in alignment not only with our values but also with our purpose.
We are part of a community that prioritizes empathy, teamwork, and progress. Stay tuned for updates on our journey and the difference we are making together.
Thank you for your continued support and for being part of this initiative. Together, we can make a difference!
#CommunitySupport#HealthcareInitiative#GivingBack#CorporateResponsibility#SummerEvent#MakingADifference
> CordenPharma hosts the 2024 Swiss Fine Chemical Association annual meeting at our Liestal, Switzerland site!
The SFCA is a group of Swiss CDMOs that meet annually at rotating locations of the member companies. This year, it was CordenPharma’s turn to host the meeting at our Liestal, CH site, organized by Managing Director Thomas Müller.
On 13 June, CordenPharma invited attendees to join for an aperitif and networking dinner.
The next day, on 14 June, Thomas Mueller was joined by CEO Michael Quirmbach, Associate Director of Sales Steffen Bira, and former Liestal Managing Director and long-time colleague Juerg Burger to host ~2 representatives from each member CDMO. A full program of inspirational speeches was organized, followed by a lively exchange amongst member companies. Speakers and topics included:
· Jade Sternberg of digitalswitzerland presented a talk on “The power of ecosystems to digitally transform a country – a perspective from Switzerland’s leading digital association.”
· Felix Georg Mueller of plus10 presented a talk on “Intelligent efficiency increase in pharma production lines though GMP-compliant AI software tools.”
· Francesco Crivelli of CSEM spoke on “AI for predictive analytics, in maintenance and quality control.”
Thomas Mueller commented, “We had an engaging dinner and full program of interesting topics impacting the CDMO landscape. It was great to welcome member companies to this event to network, exchange ideas, and as we do every year, have discussions on trends. This year we organized very informative talks on the game-changing topics of digitalization and AI that not only affect the future of pharma in Switzerland, but globally as well. We look forward to future meetings at other SFCA member locations to come!”
#SFCA#swisschemicals#cdmo#pharmamanufacturing#pharmaceuticals#CordenPharma#digitalization#AI#predictiveanalytics#supplychain
Expanding our global reach with new Lipid & LNP Starter Kit stock in Tokyo, Japan!
As we recognize the importance of access to the supply of effective pharmaceutical-grade lipids with reduced order-to-delivery times, we are excited to announce the establishment of a new lipid stock in Tokyo, Japan. This strategic move provides enhanced proximity to a specially selected group of our highly pure standard lipids, including those proven to be effective in our new Lipid NanoParticle (LNP) Starter Kits, to our valued Asian and Japanese customers.
For more information or to place an inquiry for our Japan stock of Lipids and LNP Starter Kits, click here: https://lnkd.in/ecByaKK7#cordenpharma#cdmo#lipids#japan#lnps#lipidnanoparticles#pharmaceuticals#pharma#pharmaindustry#lnp#mrna#genetherapy
> Press Release 19 June: WACKER & CordenPharma are pleased to announce their joint consortium has officially entered the pandemic readiness state as of 1 June 2024. Following a successful expansion and qualification phase, the companies are now in stand-by phase for at least five years.
In the event of a new pandemic, WACKER and CordenPharma have taken the necessary steps to produce 80 million vaccine doses a year within an extremely short time, with most of the production steps taking place in Germany, and every production step occurring within the European Union.
As part of the consortium, CordenPharma is ready to manufacture custom and standard lipids in our Frankfurt (DE) and Chenôve (FR) sites, as well as provide aseptic fill & finish and packaging of the chosen mRNA-based vaccine at our Caponago (IT) facility.
In its site in Halle (Germany), WACKER will produce plasmid DNA (pDNA), which is an essential starting material for the manufacture of mRNA.
Dr. Michael Quirmbach, CEO of CordenPharma Group, commented: “Obtaining the official confirmation of pandemic readiness by the German government is a major milestone for CordenPharma. I am extremely proud of our teams across the CordenPharma sites involved in establishing and delivering our pandemic readiness plan on schedule. We are now ready, together with our partner WACKER, to manufacture end-to-end mRNA-based vaccines for the German government and other customers.”
“We have expanded our Halle site into a Competence Center for mRNA production,” said WACKER CEO Dr. Christian Hartel. “WACKER has invested over 100 million Euros in this expansion and created over 100 highly qualified jobs. Our expertise in making mRNA and LNPs will contribute to the fight against future pandemics. Together with CordenPharma, we are proud to serve the German government in its pandemic preparedness plans.”
Read the full press release here:
https://lnkd.in/d6vBdaPK#CordenPharma#wacker#pandemic#mrna#pdna#lipids#injectables#fillfinish#pharmaceuticals#vaccine#germany
Umberto Romeo, Development Director of the Lipid Nanoparticle Manufacturing area at our facility in Caponago (IT), explains how the kits support researchers and developers with the essential components needed to create and optimize their own LNPs for #mRNA delivery.
The benefits of our kits include:
-Customization and optimization of lipid composition and formulation parameters tailored to specific mRNA-based therapeutics
-Cost effectiveness
-Rapid prototyping
-Intellectual property control
Take advantage of our 25% discount by ordering our kits before the end of June 2024. Order here: https://lnkd.in/eTK2ZSPj#cordenpharma#lipidnanoparticles#lnps#cdmo#pharmaceuticals#pharma#pharmaindustry
> PR 6 June 2024: CordenPharma & Certest Pharma Partner to Unleash the Potential of Patented Ionizable Lipids in LNP Formulation.
The partnership, signed on 7 May 2024, aims to add ionizable lipids to CordenPharma’s complex LNP formulation services, the key element needed to close the gap in our formulation offering to support biotech and pharmaceutical companies with the development, discovery, and manufacturing of xRNA / xDNA from early clinical phase to commercial.
Under the terms of the agreement, Certest will provide access to their unique ionizable lipids platform and CordenPharma will leverage cGMP manufacturing capacities, regulatory know-how, and market access to ensure high-quality GMP supply for our customers’ journey to market.
Matthieu Giraud, PhD, CordenPharma’s Senior Director, Global Lipids & Carbohydrates Platform, commented: “At CordenPharma, we independently consider each of the four lipid functional excipients of an LNP formulation to provide our customers with the most effective support in solving their therapeutic formulation challenges. This partnership augments our offer with a lean and attractive approach to LNP formulation that also reduces the growing IP challenges in the market.”
Nelson Fernandes, CEO of Certest, commented: “The world of lipid nanoparticles is revolutionizing the pharmaceutical industry today. At Certest, we offer a powerful delivery platform, thanks to our ionizable lipids, that will enable clients to overcome nearly all therapeutic challenges. This collaboration is going to be a significant advancement for our clients.”
Read the full press release here >
https://lnkd.in/evjJzmJm#CordenPharma#certest#lipidnanoparticles#lnps#lipids#mRNA#xDNA#ionizablelipids#lnpformulation#cdmo#pharmaceuticals#vaccinemanufacturing#peptides#lnpdrugdelivery
Vice President I Head Commercial Development & Strategic Marketing Mammalian I Lonza I CDMO I Board Member I INSEAD
1dGreat interview! Very insightful and lively! Represents Corden Pharma 100%.